University of Limerick Institutional Repository

Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial

DSpace Repository

Show simple item record

dc.contributor.author Stack, Austin G.
dc.contributor.author Dronamraju, Nalina
dc.contributor.author Parkinson, Joanna
dc.contributor.author Johansson, Susanne
dc.contributor.author Johnsson, Eva
dc.contributor.author Erlandsson, Fredrik
dc.contributor.author Terkeltaub, Robert
dc.date.accessioned 2021-04-14T10:36:43Z
dc.date.available 2021-04-14T10:36:43Z
dc.date.issued 2020
dc.identifier.uri http://hdl.handle.net/10344/9998
dc.description peer-reviewed en_US
dc.description.abstract Rationale & Objective: Hyperuricemia has been implicated in the development and progression of chronic kidney disease. Verinurad is a novel, potent, specific urate reabsorption inhibitor. We evaluated the effects on albuminuria of intensive urate-lowering therapy with verinurad combined with the xanthine oxidase inhibitor febuxostat in patients with hyperuricemia and type 2 diabetes mellitus (T2DM). Study Design: Phase 2, multicenter, prospective, randomized, double-blind, parallel-group, placebo-controlled trial. Setting & Participants: Patients 18 years or older with hyperuricemia, albuminuria, and T2DM. Intervention: Patients randomly assigned 1:1 to verinurad (9 mg) plus febuxostat (80 mg) or matched placebo once daily for 24 weeks. Outcomes: The primary end point was change in urinary albumin-creatinine ratio (UACR) from baseline after 12 weeks’ treatment. Secondary end points included safety and tolerability and effect on glomerular filtration. en_US
dc.language.iso eng en_US
dc.publisher Elsevier en_US
dc.relation.ispartofseries American Journal of Kidney Diseases(AJKD);77(4), pp.481-489.
dc.subject type 2 diabetes en_US
dc.subject Hyperuricemia en_US
dc.title Effect of intensive urate lowering with combined verinurad and febuxostat on albuminuria in patients with type 2 diabetes: A randomized trial en_US
dc.type info:eu-repo/semantics/article en_US
dc.type.supercollection all_ul_research en_US
dc.type.supercollection ul_published_reviewed en_US
dc.identifier.doi 10.1053/j.ajkd.2020.09.009
dc.contributor.sponsor AstraZeneca en_US
dc.contributor.sponsor HRB
dc.contributor.sponsor
dc.relation.projectid HRA-2013-PHR-437
dc.rights.accessrights info:eu-repo/semantics/openAccess en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search ULIR


Browse

My Account

Statistics